More details have emerged over why AstraZeneca paused its Phase 3 COVID-19 vaccine trial in Britain. During a private call with investors, AstraZeneca’s CEO revealed a woman in the trial developed severe neurological symptoms consistent with transverse myelitis, or inflammation of the spinal cord. Details about the phone call were first reported by the medical news site STAT.
Topics: